| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 21,418 | 20,648 | ||
| Short-term investments | 15,042 | 20,346 | ||
| Prepaid expenses and other current assets | 1,983 | 2,136 | ||
| Total current assets | 38,443 | 43,130 | ||
| Property and equipment, net | 60 | 68 | ||
| Intangible assets, net | 338 | 354 | ||
| Operating lease right-of-use assets | 163 | 181 | ||
| Other non-current assets | 17 | 17 | ||
| Total assets | 39,021 | 43,750 | ||
| Accounts payable | 4,078 | 2,425 | ||
| Accrued expenses | 6,849 | 8,144 | ||
| Operating lease liabilities, current portion | 113 | 109 | ||
| Total current liabilities | 11,040 | 10,678 | ||
| Operating lease liabilities, net of current portion | 115 | 145 | ||
| Total liabilities | 11,155 | 10,823 | ||
| Common stock, 0.001 par value 150,000,000 shares and 58,251,629 shares authorized as of september 30, 2025 and december 31, 2024, respectively 9,379,332, and 2,574,767 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 9 | 9 | ||
| Additional paid-in capital | 131,025 | 130,579 | ||
| Accumulated other comprehensive income | 7 | -13 | ||
| Accumulated deficit | -103,175 | -97,648 | ||
| Total stockholders' equity (deficit) | 27,866 | 32,927 | ||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | 39,021 | 43,750 | ||
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)